An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

Launched by EPIMMUNE · Feb 13, 2003

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of Non-Small Cell Lung Cancer, stage IIb or IIIa
• • At least four weeks following prior standard treatment, with no evidence of disease
• • Must use adequate birth control
• Exclusion Criteria:
• • Prior cancer vaccine therapy or concurrent participation in any other investigational study
• • A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment
• • A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine
• • Women who are pregnant, intend to become pregnant, or who are breast feeding